메뉴 건너뛰기
Pharmacotherapy
Volumn 26, Issue 8 I, 2006, Pages 1201-1202
Antiplatelet drug resistance: Almost ready for prime time
Author keywords

Antiplatelet resistance; Aspirin resistance
Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;
EID: 33746735533     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.8.1201     Document Type: Short Survey
Times cited : (1)
References (8)
  • 1
    • 27644559048 scopus 로고    scopus 로고
    • Antiplatelet drug resistance: Not ready for prime time
    • Burns TL, Mooss AN, Hilleman DE. Antiplatelet drug resistance: not ready for prime time. Pharmacotherapy. 2005;25:1621-8.
    • (2005) Pharmacotherapy , vol.25 , pp. 1621-1628
    • Burns, T.L.1    Mooss, A.N.2    Hilleman, D.E.3
  • 3
    • 2942555599 scopus 로고    scopus 로고
    • Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer
    • Malinin A, Spergling M, Muhlestein B, Steinhubl SR, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301.
    • (2004) Blood Coagul Fibrinolysis , vol.15 , pp. 295-301
    • Malinin, A.1    Spergling, M.2    Muhlestein, B.3    Steinhubl, S.R.4    Serebruany, V.5
  • 4
    • 21244446907 scopus 로고    scopus 로고
    • Low-dose aspirin increases aspirin resistance in patients with coronary artery disease
    • Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;188:723-7.
    • (2005) Am J Med , vol.188 , pp. 723-727
    • Lee, P.Y.1    Chen, W.H.2    Ng, W.3
  • 5
    • 1642453779 scopus 로고    scopus 로고
    • Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
    • Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71.
    • (2004) Circulation , vol.109 , pp. 166-171
    • Lau, W.C.1    Gurbel, P.A.2    Watkins, P.B.3
  • 6
    • 0037422534 scopus 로고    scopus 로고
    • Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction
    • Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7.
    • (2003) Circulation , vol.107 , pp. 32-37
    • Lau, W.C.1    Waskell, L.A.2    Watkins, P.B.3
  • 7
    • 0042780283 scopus 로고    scopus 로고
    • Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    • Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4.
    • (2003) Circulation , vol.108 , pp. 921-924
    • Saw, J.1    Steinhubl, S.R.2    Berger, P.B.3
  • 8
    • 29344457180 scopus 로고    scopus 로고
    • ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention
    • Smith SC, Feldman TE, Hirshfield JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2006;47:e1-121.
    • (2006) J Am Coll Cardiol , vol.47
    • Smith, S.C.1    Feldman, T.E.2    Hirshfield, J.W.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.